Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Variant Bio
company
About
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $105M
- Industries
- Biotechnology,Genetics,Medical,Therapeutics
- Founded date
- Jan 1, 2018
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics. The company's focus is to identify individuals and populations around the world who are extreme outliers for traits of medical relevance and to use innovative sequencing and analytic approaches to identify genes and pathways linked to these traits.Variant Bio was founded in 2018 and headquartered in Seattle, Washington.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$105M
Variant Bio has raised a total of
$105M
in funding over 2 rounds. Their latest funding was raised on
Nov 9, 2021 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 9, 2021 | Series B | $105M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Variant Bio is funded by 1 investors.
General Catalyst
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
General Catalyst
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
